Bjorn R. Thomas

Bjorn R. Thomas

Auto-generated profile, based on publicly available information

Bjorn R. Thomas

St John’s Institute of Dermatology, Guy’s and St Thomas’ National Health Service Trust, London, United Kingdom

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2023 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
CFCarsten Flohr
Carsten Flohr
ARAnna Rosala-Hallas
Anna Rosala-Hallas
AJAshley P Jones
Ashley P Jones
PBPaula Beattie
Paula Beattie
SBSusannah Baron
Susannah Baron
AIAlan D Irvine
Alan D Irvine
Background: Conventional systemic drugs are used to treat children and young people (CYP) with severe atopic dermatitis (AD) worldwide, but no robust randomized controlled trial (RCT) evidence exists regarding their efficacy and safety in this population. While novel therapies have expanded therapeutic options, their high cost means traditional agents remain important, especially in lower-resource settings. Objectives: To compare the safety and efficacy of ciclosporin (CyA) with methotrexate (MTX) in CYP with severe AD in the TREatment of severe Atopic Eczema Trial (TREAT) trial. Methods: We conducted a parallel group assessor-blinded RCT in 13 UK and Irish centres. Eligible participants aged 2–16 years and unresponsive to potent topical treatment were randomized to either oral CyA (4 mg kg–1 daily) or MTX (0.4 mg kg–1 weekly) for 36 weeks and followed-up for 24 weeks. Co-primary outcomes were change from baseline to 12 weeks in Objective Severity Scoring of Atopic Dermatitis (o-SCORAD) and time to first significant flare (relapse) after treatment cessation. Secondary outcomes included change in quality of life (QoL) from baseline to 60 weeks; number of participant-reported flares following treatment cessation; proportion of participants achieving ≥ 50% improvement in Eczema Area and Severity Index (EASI 50) and ≥ 75% improvement in EASI (EASI 75); and stratification of outcomes by filaggrin status. Results: In total, 103 participants were randomized (May 2016–February 2019): 52 to CyA and 51 to MTX. CyA showed greater improvement in disease severity by 12 weeks [mean difference in o-SCORAD –5.69, 97.5% confidence interval (CI) –10.81 to –0.57 (P = 0.01)]. More participants achieved ≥ 50% improvement in o-SCORAD (o-SCORAD 50) at 12 weeks in the CyA arm vs. the MTX arm [odds ratio (OR) 2.60, 95% CI 1.23–5.49; P = 0.01]. By 60 weeks MTX was superior (OR 0.33, 95% CI 0.13–0.85; P = 0.02), a trend also seen for ≥ 75% improvement in o-SCORAD (o-SCORAD 75), EASI 50 and EASI 75. Participant-reported flares post-treatment were higher in the CyA arm (OR 3.22, 95% CI 0.42–6.01; P = 0.02). QoL improved with both treatments and was sustained after treatment cessation. Filaggrin status did not affect outcomes. The frequency of adverse events (AEs) was comparable between both treatments. Five (10%) participants on CyA and seven (14%) on MTX experienced a serious AE. Conclusions: Both CyA and MTX proved effective in CYP with severe AD over 36 weeks. Participants who received CyA showed a more rapid response to treatment, while MTX induced more sustained disease control after discontinuation.

13 October 2021 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
XTX. L. Tan
X. L. Tan
BTB. R. Thomas
B. R. Thomas
YTY. J. Tan
Y. J. Tan
EOE. A. O’tOole
E. A. O’tOole

25 February 2023 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
BTBjorn R Thomas
Bjorn R Thomas
XTXiang Li Tan
Xiang Li Tan
SDStefan Van Duijvenboden
Stefan Van Duijvenboden
SHSarah C Hogan
Sarah C Hogan
AHAaron J Hughes
Aaron J Hughes
EOEdel A O’tOole
Edel A O’tOole
Hyperlinear palms are described as a feature of loss-of-function (LoF) variants in Filaggrin (FLG). To explore the phenotype of participants (age <31 years) with atopic eczema of Bangladeshi ancestry from East London and investigate which factors best associate with LoF FLG variants. A cross-sectional study with participants recruited between May 2018 and March 2020. Patterns of palmar linearity were categorised and modelled with Eczema Area and Severity Index (EASI), transepidermal water loss (TEWL), skin hydration (SH) and LoF FLG variants. Five hundred and six complete cases were available. Five palm patterns were noted. The ‘prominent diamond’ pattern associated best with EASI (marginal effects [ME], 2.53, 95% CI 1.74-3.67), TEWL (ME 1.32, 95% CI 1.11-1.62) and SH (ME 0.85, 95% CI 0.78-0.96). Using five palm patterns had some ability to discriminate LoF FLG variants (area under the receiver operator characteristic [AUROC] 76.07; 95% CI 71.58-80.57), improving in subgroup analysis with only fine perpendicular/prominent diamond patterns and SH (AUROC 89.11%; 95% CI 84.02-94.19). Single centre study design with humans classifying clinical patterns. Stability of temperature and humidity not guaranteed across TEWL and SH measurements despite using a climate controlled room. Palm patterns associate with EASI and TEWL. The fine perpendicular/prominent diamond patterns are markers to detect absence/presence of LoF FLG variants respectively.

25 December 2019 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
BTB.R. Thomas
B.R. Thomas
ASA. Sahota
A. Sahota

20 December 2022 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
STSoha S Tawfik
Soha S Tawfik
BTBjorn R Thomas
Bjorn R Thomas
DKDavid Kelsell
David Kelsell
JGJonathan Grigg
Jonathan Grigg
EOEdel A O’tOole
Edel A O’tOole
Background: Atopic eczema (AE) is a chronic relapsing, pruritic disease that greatly affects the child and family’s quality of life (QoL). It is usually common and severe among children of Bangladeshi ethnicity. Objectives: This is a cross-sectional quantitative study in patients with AE of Bangladeshi origin, which aims to analyse different components of the family, children and adult quality-of-life indices and their relationship to patient age, sex, eczema severity and distribution, other allergic associations, parental education and socioeconomic level. Methods: Children and young adults of Bangladeshi origin aged 0–30 years, clinically diagnosed with AE were recruited as part of the Tower Hamlets Eczema Assessment project, a clinical phenotyping study of AE in the Bangladeshi population living in East London. Questionnaires completed by children/parents included the Family Dermatology Life Quality Index (FDLQI), Infant’s Dermatology Quality of Life (IDQOL) and the Children’s Dermatology Life Quality Index (CDLQI). Young adults completed the Dermatology Life Quality Index (DLQI). The disease severity was assessed objectively using the Eczema Area Severity Index (EASI). Patients and parents who did not read or speak English were aided by Bengali/Sylheti-speaking research assistants. Results: Overall, 460 Bangladeshi children and 98 adults with AE were recruited. Burden of care, extra housework and emotional distress were the highest affected domains in parental QoL, while itching and sleep were the highest for children. Significant factors influencing FDLQI score were EASI [marginal effect (ME) 1.01, 95% confidence interval (CI) 1.00–1.03; P = 0.004], age (ME 0.98, 95% CI 0.97–0.99; P = 0.004), extensor eczema distribution (ME 1.25, 95% CI 1.03–1.52; P = 0.023), parental English fluency (ME 1.29, 95% CI 1.10–1.52; P = 0.002) and atopic comorbidities (ME 1.10, 95% CI 1.04–1.17; P = 0.001). Parental socioeconomic class was a nonsignificant factor. IDQOL/CDLQI was influenced significantly by the child’s age (ME 0.99, 95% CI 0.97–1.00, P = 0.023), ‘nonclear’ eczema distribution clusters especially the ‘severe extensive’ cluster (ME 1.46, 95% CI 1.15–1.84; P = 0.002) and nonsignificantly by EASI and parental English literacy and socioeconomic levels. DLQI was affected significantly by nonclear eczema distribution groups especially ‘severe extensive’ (ME 2.49, 95% 1.76–3.53; P < 0.001) and nonsignificantly by patient age, and female sex. Conclusions: AE is a chronic disease where many external factors other than disease severity affect QoL of patients and their families, ­especially in under-represented minority groups who face different linguistic and cultural barriers.

11 August 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
BTBjorn R Thomas
Bjorn R Thomas